{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T02:41:46Z","timestamp":1725504106438},"publisher-location":"Boston, MA","reference-count":61,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9780387293455"},{"type":"electronic","value":"9780387293462"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/978-0-387-29346-2_4","type":"book-chapter","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T06:38:51Z","timestamp":1204612731000},"page":"121-140","source":"Crossref","is-referenced-by-count":4,"title":["Diffuse Large B-Cell NHL"],"prefix":"10.1007","author":[{"given":"Jonathan W.","family":"Friedberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"J.O. Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol 16:2780\u201395., 1998","journal-title":"J Clin Oncol"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"R.T. Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15\u201336, 2001","journal-title":"CA Cancer J Clin"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2004.02.104","volume":"22","author":"S.T. Hehn","year":"2004","unstructured":"Hehn ST, Grogan TM, Miller TP: Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 22:3046\u201352, 2004","journal-title":"J Clin Oncol"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"N.L. Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835\u201349., 1999","journal-title":"J Clin Oncol"},{"key":"4_CR5","first-page":"245","volume":"115","author":"R.S. Doggett","year":"1984","unstructured":"Doggett RS, Wood GS, Horning S, et al: The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115:245\u201352, 1984","journal-title":"Am J Pathol"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0065-230X(08)60456-X","volume":"42","author":"H. Stein","year":"1984","unstructured":"Stein H, Lennert K, Feller AC, et al: Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 42:67\u2013147, 1984","journal-title":"Adv Cancer Res"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"N.L. Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al: Perspective: A Revised European-American Classificiation of Lymphoid Neoplasm: A Proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392, 1994","journal-title":"Blood"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2001.19.6.1855","volume":"19","author":"K. Besien van","year":"2001","unstructured":"van Besien K, Kelta M, Bahaguna P: Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 19:1855\u201364, 2001","journal-title":"J Clin Oncol"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"K.J. Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871\u20139, 2003","journal-title":"Blood"},{"key":"4_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","volume":"127","author":"A.J. Ferreri","year":"2004","unstructured":"Ferreri AJ, Campo E, Seymour JF, et al: Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u2018cutaneous variant\u2019. Br J Haematol 127:173\u201383, 2004","journal-title":"Br J Haematol"},{"key":"4_CR11","first-page":"339","volume":"87","author":"V. Ascoli","year":"2002","unstructured":"Ascoli V, Lo Coco F, Torelli G, et al: Human herpes virus 8-associated primary effusion lymphoma in HIV\u2014patients: a clinicopidemiologic variant resembling classic Kaposi\u2019s sarcoma. Haematologica 87:339\u201343, 2002","journal-title":"Haematologica"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V90.1.244","volume":"90","author":"R.D. Gascoyne","year":"1997","unstructured":"Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin\u2019s lymphoma. Blood 90:244\u201351, 1997","journal-title":"Blood"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1056\/NEJM199407143310202","volume":"331","author":"K. Offit","year":"1994","unstructured":"Offit K, LoCoco F, Louie DC, et al: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N.Engl.J.Med. 331:74\u201380, 1994","journal-title":"N.Engl.J.Med."},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"A.A. Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u201311, 2000","journal-title":"Nature"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A. Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, et al: The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large B-Cell Lymphoma. N.Engl.J.Med. 346:1937\u20131947, 2002","journal-title":"N.Engl.J.Med."},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"M.A. Shipp","year":"2002","unstructured":"Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68\u201374, 2002","journal-title":"Nat Med"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S. Monti","year":"2005","unstructured":"Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851\u201361, 2005","journal-title":"Blood"},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa032520","volume":"350","author":"I.S. Lossos","year":"2004","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828\u201337, 2004","journal-title":"N Engl J Med"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1634\/theoncologist.8-5-438","volume":"8","author":"J.W. Friedberg","year":"2003","unstructured":"Friedberg JW, Chengazi V: PET Scans in the Staging of Lymphoma: Current Status. Oncologist 8:438\u201347, 2003","journal-title":"Oncologist"},{"key":"4_CR20","first-page":"1860","volume":"31","author":"P.P. Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res 31:1860\u20131, 1971","journal-title":"Cancer Res"},{"key":"4_CR21","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329:987\u201394, 1993","DOI":"10.1056\/NEJM199309303291402"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V43.2.181.181","volume":"43","author":"P.S. Schein","year":"1974","unstructured":"Schein PS, Chabner BA, Canellos GP, et al: Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin\u2019s lymphoma. Blood 43:181\u20139, 1974","journal-title":"Blood"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1200\/JCO.1989.7.9.1186","volume":"7","author":"S.E. Jones","year":"1989","unstructured":"Jones SE, Miller TP, Connors JM: Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7:1186\u201391, 1989","journal-title":"J Clin Oncol"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1989.7.9.1179","volume":"7","author":"D.L. Longo","year":"1989","unstructured":"Longo DL: Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 7:1179\u201381, 1989","journal-title":"J Clin Oncol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"T.P. Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin\u2019s lymphoma. N.Engl.J.Med. 339:21\u201326, 1998","journal-title":"N.Engl.J.Med."},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1182\/blood.V98.3.705","volume":"98","author":"T.P. Miller","year":"2001","unstructured":"Miller TP, LeBlanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin\u2019s lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724\u20135a, 2001","journal-title":"Blood"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/JCO.2004.05.926","volume":"22","author":"T.P. Miller","year":"2004","unstructured":"Miller TP: The limits of limited stage lymphoma. J Clin Oncol 22:2982\u20134, 2004","journal-title":"J Clin Oncol"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.20.1.197","volume":"20","author":"T.N. Shenkier","year":"2002","unstructured":"Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197\u2013204, 2002","journal-title":"J Clin Oncol"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","volume":"22","author":"S.J. Horning","year":"2004","unstructured":"Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032\u20138, 2004","journal-title":"J Clin Oncol"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1056\/NEJMoa042040","volume":"352","author":"F. Reyes","year":"2005","unstructured":"Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197\u2013205, 2005","journal-title":"N Engl J Med"},{"key":"4_CR31","first-page":"92a","volume":"100","author":"G. Fillet","year":"2002","unstructured":"Fillet G, Bonnet C, Mournier N, et al: Radiotherapy is unnecessary in elderly patients with localized aggressive non Hodgkin\u2019s lymphoma: Results of the GELA LNH 93\u20134 study. Blood 100:92a, 2002","journal-title":"Blood"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"48a","DOI":"10.1182\/blood.V104.11.48.48","volume":"104","author":"T.P. Miller","year":"2004","unstructured":"Miller TP, Unger JM, Spier C, et al: Effect of adding rituximab to three cycles of CHOP plus involved field radiotherapy for limited-stage aggressive diffuse B cell lymphoma, SWOG 0014. Blood 104:48a, 2004","journal-title":"Blood"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1054\/bjoc.2000.1566","volume":"84","author":"A. Messori","year":"2001","unstructured":"Messori A, Vaiani M, Trippoli S, et al: Survival in patients with intermediate or high grade non-Hodgkin\u2019s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303\u20137, 2001","journal-title":"Br J Cancer"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","volume":"327","author":"L.I. Gordon","year":"1992","unstructured":"Gordon LI, Harrington D, Andersen J, et al: Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin\u2019s Lymphoma. N.Engl.J.Med. 327:1342\u20131349, 1992","journal-title":"N.Engl.J.Med."},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"R.I. Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 328:1002\u20136, 1993","journal-title":"N Engl J Med"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"J.M. Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 19:389\u201397, 2001","journal-title":"J Clin Oncol"},{"key":"4_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B. Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u201342, 2002","journal-title":"N Engl J Med"},{"key":"4_CR38","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","volume":"101","author":"N. Mounier","year":"2003","unstructured":"Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2014associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279\u201384, 2003","journal-title":"Blood"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood.V102.1.6.6","volume":"102","author":"T.M. Haberman","year":"2003","unstructured":"Haberman TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood 102:6a, 2003","journal-title":"Blood"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"48a","DOI":"10.1182\/blood.V104.11.48.48","volume":"104","author":"M. Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Truemper L, Gill D, et al: First analysis of the completed Mabthera international trial in young patients with low-risk diffuse large B cell lymphoma: addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 104:48a, 2004","journal-title":"Blood"},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1200\/JCO.2003.06.137","volume":"21","author":"D.W. Blayney","year":"2003","unstructured":"Blayney DW, LeBlanc ML, Grogan T, et al: Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21:2466\u201373, 2003","journal-title":"J Clin Oncol"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M. Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634\u201341, 2004","journal-title":"Blood"},{"key":"4_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M. Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u201333, 2004","journal-title":"Blood"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T. Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20135, 1995","journal-title":"N Engl J Med"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","volume":"18","author":"C. Haioun","year":"2000","unstructured":"Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: Final analysis of the Prospective LNH87-2 Protocol-A Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Study. J.Clin.Oncol. 18:3025\u20133030, 2000","journal-title":"J.Clin.Oncol."},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","volume":"16","author":"G. Santini","year":"1998","unstructured":"Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin\u2019s lymphoma: results of a prospective randomized trial by the non-Hodgkin\u2019s lymphoma cooperative study group. J.Clin.Oncol. 16:2796\u20132802, 1998","journal-title":"J.Clin.Oncol."},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","volume":"93","author":"H.C. Kluin-Nelemans","year":"2000","unstructured":"Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al: Standard Chemotherapy with or without High-Dose Chemotherapy for Aggressive Non-Hodgkin\u2019s Lymphoma: Randomized Phase III EORTC Study. J.Nat.Cancer Inst. 93:22\u201330, 2000","journal-title":"J.Nat.Cancer Inst."},{"key":"4_CR48","doi-asserted-by":"crossref","unstructured":"Kaiser U, Uebelacker I, Abel U, et al: A Randomized Study to Evaluate The Use of High-Dose Therapy As Part Of Primary Treatment for \u2018Aggressive\u2019 Lymphoma. J.Clin.Oncol., 2002","DOI":"10.1200\/JCO.2002.07.075"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","volume":"336","author":"A.M. Gianni","year":"1997","unstructured":"Gianni AM, Bregni M, Siena S, et al: High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N.Engl.J.Med. 336:1290\u20131297, 1997","journal-title":"N.Engl.J.Med."},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","volume":"20","author":"C. Gisselbrecht","year":"2002","unstructured":"Gisselbrecht C, Lepage E, Molina T, et al: Shortened First-Line High-Dose Chemotherapy For Patients With Poor-Risk Aggressive Lymphoma. J.Clin.Oncol. 20:2472\u20132479, 2002","journal-title":"J.Clin.Oncol."},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","volume":"332","author":"L.F. Verdonck","year":"1995","unstructured":"Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin\u2019s Lymphoma. N.Engl.J.Med. 332:1045\u20131051, 1995","journal-title":"N.Engl.J.Med."},{"key":"4_CR52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa031770","volume":"350","author":"N. Milpied","year":"2004","unstructured":"Milpied N, Deconinck E, Gaillard F, et al: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287\u201395, 2004","journal-title":"N Engl J Med"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","volume":"17","author":"J.W. Friedberg","year":"1999","unstructured":"Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:3128\u201335, 1999","journal-title":"J Clin Oncol"},{"key":"4_CR54","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","volume":"23","author":"J.R. Brown","year":"2005","unstructured":"Brown JR, Yeckes H, Friedberg JW, et al: Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin\u2019s Lymphoma. J Clin Oncol 23:2208\u201314, 2005","journal-title":"J Clin Oncol"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","volume":"17","author":"M.A. Shipp","year":"1999","unstructured":"Shipp MA, Abeloff MD, Antman KH, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin\u2019s lymphomas: Report of the jury. J.Clin.Oncol. 17:423\u2013429, 1999","journal-title":"J.Clin.Oncol."},{"key":"4_CR56","first-page":"1927","volume":"92","author":"B. Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927\u201332, 1998","journal-title":"Blood"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"41a","DOI":"10.1182\/blood.V104.11.41.41","volume":"104","author":"F. Morschhauser","year":"2004","unstructured":"Morschhauser F, Huglo D, Martinelli G, et al: Yttrium-90 Ibribumomab tiuxetan for patients with relapsed\/refractroy diffuse large B cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 104:41a, 2004","journal-title":"Blood"},{"key":"4_CR58","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T. Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684\u20138, 2004","journal-title":"Blood"},{"key":"4_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2141.2004.05251.x","volume":"128","author":"K.S. Peggs","year":"2005","unstructured":"Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Br J Haematol 128:153\u201368, 2005","journal-title":"Br J Haematol"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","volume":"22","author":"M.P. Escalon","year":"2004","unstructured":"Escalon MP, Champlin RE, Saliba RM, et al: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin\u2019s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419\u201323, 2004","journal-title":"J Clin Oncol"},{"key":"4_CR61","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-04-0922","volume":"10","author":"J.W. Friedberg","year":"2004","unstructured":"Friedberg JW: Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res 10:5297\u20138, 2004","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment and Research","Hodgkin\u2019s and Non-Hodgkin\u2019s Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-0-387-29346-2_4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T21:16:38Z","timestamp":1605647798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-0-387-29346-2_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["9780387293455","9780387293462"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/978-0-387-29346-2_4","relation":{},"subject":[]}}